- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00627848
Rivastigmine in Mild Alzheimer's Disease, FMRI Study (ADFRMI)
October 27, 2011 updated by: Hilkka Soininen, Kuopio University Hospital
Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease
The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task.
Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kuopio, Finland, 70211
- Kuopio University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Probable Alzheimer's disease according to the NINCDS-ADRDA criteria
- mild disease, CDR 1
- the clinician is planning to start anticholinesterase treatment
Exclusion Criteria:
- cognitive impairment for other reason than Alzheimer's disease
- severe depression
- other unstable physical disease
- medal in body prevention MRI examination, claustrophobia
- cardiac pacemaker
- other significant neurologic or psychiatric disease
- contraindication for anticholinesterase treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
FMRI response in face recognition task
Time Frame: at baseline and at 1 mo
|
at baseline and at 1 mo
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
treatment response measured by ADAS-cog
Time Frame: at 6 month and 1 year
|
at 6 month and 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hilkka Soininen, Kuopio University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
February 22, 2008
First Submitted That Met QC Criteria
February 22, 2008
First Posted (Estimate)
March 3, 2008
Study Record Updates
Last Update Posted (Estimate)
October 28, 2011
Last Update Submitted That Met QC Criteria
October 27, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Neuroprotective Agents
- Protective Agents
- Cholinesterase Inhibitors
- Rivastigmine
Other Study ID Numbers
- KUH5772749
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer' Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on rivastigmine
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedMild to Moderate Alzheimer's DiseaseJapan
-
Novartis PharmaceuticalsCompletedAlzheimer DiseaseUnited States, Germany, Italy, Spain, France, Canada, Switzerland
-
Federal University of BahiaCompletedAlzheimer DiseaseBrazil
-
NovartisCompletedParkinson's Disease DementiaUnited States, Belgium, Italy, United Kingdom, Germany, Australia, Austria, Spain, Canada, France, Netherlands, Turkey, Argentina
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
NovartisCompleted
-
NovartisCompletedAlzheimer's DiseaseUnited States
-
Novartis PharmaceuticalsCompleted